Objective: To screen for cognitive and behavioral impairment in people with amyotrophic lateral sclerosis (ALS) and controls with neuromuscular disease and to correlate these with clinical features. 
A C C E P T E D M A N U S C R I P T Introduction
Amyotrophic lateral sclerosis is defined by progressive loss of upper and lower motor neurones [1] . Some people with ALS also have frontotemporal dementia (FTD) while others have lesser degrees of cognitive impairment [2] . Some of the overlap between ALS and FTD is associated with the presence of a C9orf72 gene mutation [3, 4] . Different approaches have been used to study the frequency of cognitive impairment. Full neuropsychological testing is time-consuming. Therefore a variety of simple tools have been used to screen for cognitive impairment in ALS. These include Addenbrooke's cognitive examination-III (ACE-III), an updated version of the ACE-R [5] [6] [7] [8] , the Frontal assessment battery (FAB) [9] [10] [11] , the Edinburgh cognitive and behavioral ALS screen (ECAS), which includes tests of social cognition, [12] [13] [14] [15] [16] and the ALS cognitive behavioral screen (ALS CBS) [17] . Table 1 shows the elements tested in the different tools. Other scales have been developed to detect behavioral dysfunction in ALS [18, 19] . These include the Amyotrophic lateral sclerosis-Frontotemporal dementia questionnaire (ALS-FTD-Q) and the Motor Neurone Disease Behavioural instrument (MiND-B), which are administered to carers.
With such screening tools, the incidence of the cognitive impairment in ALS ranges from 30 to 75% [20] [21] [22] [23] and the rate of behavioral impairment ranges from 14%
to 40% [12, [23] [24] [25] (Table 2) .
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Current evidence suggest that some people with ALS have cognitive and behavioral impairment, and others do not. The cause of this is unclear. As already mentioned, carriage of a repeat expansion in C9orf72 is a cause of cognitive impairment in ALS, but there could be other factors. There have been attempts to determine whether clinical features are correlated with the presence of cognitive and behavioral testing. Some studies have found cognitive impairment to be more common in people with bulbar onset than limb onset of ALS [32] . However, other studies suggest that site of onset has no influence on the presence of cognitive impairment [33] [34] [35] . Therefore further information is required.
There have also been studies of whether the presence of cognitive or behavioral impairment affects prognosis, as might be the case if the presence of cognitive impairment indicates more severe or widespread disease. Some studies have suggested that the presence of cognitive impairment [36] or behavioral abnormality is associated with worse prognosis [37] . However, other studies suggest that cognitive impairment has no influence on survival [35] . Therefore further information is required.
Another possibility is that cognitive impairment, and other extramotor features of ALS, might develop in all people with ALS over time, as disease spreads more widely [38] . If this were the case, cognitive impairment would correlate with disease severity, but there is little information about this. There is conflicting information about whether there is later development of cognitive impairment in patients who are cognitively normal at onset of ALS [39] [40] [41] [42] . Further information is required about this issue as well.
The first aim of the present study is to measure cognitive and behavioral impairment in the ALS patients by using 5 different clinic based questionnaires (ACE- and that age and education would influence cognition in ALS, as is the case in healthy people [43] and that cognitive impairment is related to disease severity as would be the case if cognitive impairment occurs with more severe and widespread disease. The rationale for this was to provide further information about this unresolved issue. The third aim is to evaluate the effects of cognitive and behavioral impairment on survival, with the hypothesis that the presence of cognitive impairment indicates more severe and wide spread disease, and would be expected to worsen prognosis.
The final aim is to determine if there is deterioration in cognition over time. The reasoning behind this study was to investigate whether patients who are cognitively normal at onset develop dysfunction over time, or whether ALS can be divided into people with cognitive issues and people without cognitive issues.
Methodology

Subjects:
People with probable or definite ALS [1] were recruited from the multidisciplinary MND clinic at Royal Brisbane and Women's Hospital (RBWH). The 
Clinical details:
The age, gender, the date of onset of symptoms and the site of onset of symptoms were recorded. The revised ALS Functional Rating Scale (ALS-FRS-R) [44] was recorded at each visit. When applicable, the date of death was recorded and the length of survival from onset of disease to death or censoring was calculated.
Cognitive and behavioral tests
All participants were tested with the ACE-III, which has a maximum possible score of 100. A score of less than 88 was defined as possible cognitive impairment [45] .
The FAB, with a maximum possible score of 18, was also administered to all participants. A score of less than 12 was regarded as high possibility of cognitive impairment [10] .
The executive function section of the ECAS (which includes reverse digit span, alternation, sentence completion and social cognition) was added to the testing panel
later in the study. It was administered to 41 people with ALS and 30 controls. The cutoff value for cognitive impairment is 33 of 48 [12] . Some people with ALS were unable to complete the tests due to physical disability. This was the case for 19 people for the ACE-III and for 3 for the FAB. To deal with this, we calculated the percentage of correct responses of the items that were tested, and then estimated the final score as this percentage of the total possible. This approach is an approximation, but has been used by others in this field [46] . respectively [18, 19] . The relationship between the carer and the person with ALS was also recorded.
To evaluate any changes over time, serial cognitive tests, at intervals of 6 months or more, were obtained from 37 patients.
Statistical analysis
Statistical analysis was performed with SPSS 20 software. To compare groups, ANOVA was used, if the variables were normally distributed. Otherwise, the data were compared with the Mann-Whitney U test for two independent groups. To compare the proportions of groups, the χ 2 test was used. To determine whether cognitive and behavioral function were influenced by clinical features, multiple logistic regression was used to evaluate the effects of age, gender, disease duration at the time of testing, years of education, site of onset and relationship of the carer to the person with ALS, To determine whether there was an association between disease severity measured by ALSFRS-R and scores of cognitive and behavioral testing, we used the Spearman rank test. To assess the effects of cognition and behavior on survival, Kaplan-Meier curve
and log rank test were utilized to compare survival between patients with normal and those with abnormal results. A Cox proportional regression model was used to report the hazard ratio and 95% confidence interval for each cofactor affecting prognosis. A generalized estimating equation model was used to test the longitudinal data. The model based estimator was chosen in the covariance matrix. Unstructured working correlation matrix was selected. P<0.05 was considered as significant.
Results
Clinical features
Clinical features of patients and controls, and numbers of participants for each test, are given in Table 3 . The diagnoses of the people with neuromuscular disease are given in Error! Reference source not found.. A C C E P T E D M A N U S C R I P T The frequency distributions of ACE-III and FAB scores in disease controls and ALS patients are shown in Figure 1 . The cognitive test scores are summarized in Table   5 . There are significant differences in total ACE-III, ACE-III attention and language scores and FAB total score between the groups. There were no significant differences in the other components of the ACE-III or in the executive section of the ECAS. The percentages of each group with cognitive impairment are shown in Table 6 . Between people with ALS and controls there is a significant difference in the percentage with abnormal results of ACE-III and FAB. However, no significant differences were found between the two groups in the scores of ECAS executive function and social cognition.
Of the patients with known causative genes, one with C9orf72 repeat expansion had normal cognitive function, and the other patients (2 with C9orf72 repeat expansions, one with TARDBP mutation and one with SOD1 mutation) had cognitive impairment, defined as abnormal result on ACE-III testing. The behavioral test scores are shown in Table 7 . The frequencies of behavioral impairment measured by ALS-FTD-Q and MiND-B are 32.1% and 39.4% respectively.
The rates of disinhibition, apathy and stereotypical behaviour are 9.1%, 21.2% and 7.6%, respectively. 
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We assessed the correlation between disease severity measured by ALSFRS-R and cognitive function measured by ACE-III, FAB and ECAS by using Spearman correlation tests (Supplementary 2 file) . There was no significant correlation. This indicates that cognition does not worsen as the disease becomes more severe.
We also tested the relationship between disease severity and behavioral testing.
The Spearman correlation tests between ALS-FTD-Q or MiND-B and ALSFRS-R score are shown in Figure 2 . There is a significant negative relationship between ALS-FTD-Q and ALSFRS-R score. There is a significant positive association between
MiND-B and ALSFRS-R score. This indicates that behavioral impairment becomes worse as disease becomes more advanced.
Correlation with the survival time in cognitive and behavioral tests
We then investigated the effect on survival of cognitive and behavioral 
The longitudinal study of cognition
We performed a longitudinal study of 37 people with ALS. This was to determine whether cognitive impairment develops over time in people who are cognitively normal on first testing. The longitudinal curves for 37 patients with different sites of onset based on ACE-III and FAB are presented in Figure 4 and Figure   5 respectively. The five domains of ACE-III serial tests results are shown in Supplementary 4 file. Some patients show a decline with serial testing, but most do not.
There were fewer tests for the third and fourth time points due to death or advanced progression of the patients.
For statistical analysis, we used generalized estimating equations for the first two tests of ACE-III and FAB (Supplementary 4 file) . The GEE analysis for ACE-III found that there was no significant difference between the first two consecutive tests (P=0.080). However, patients with bulbar onset of ALS have 3.25 higher ACE-III scores than the patients with lower limb onset over the time course (P=0.033).
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The GEE analysis for FAB found no significant difference between the first two serial tests (P=1.00). For FAB, the site of onset did not affect the results of FAB performance over time (P=0.190).
Discussion
This study assessed cognition and behaviour in people with ALS by using simple clinic based testing. As comparison we used people with neuromuscular disease.
in our cohort, the prevalence of cognitive impairment was approximately 30% and 14%
based on ACE-III and FAB, respectively This is similar to the rates of cognitive impairment found in previous studies [13, 16] ( Table 2 ). The prevalence of behavioral impairment in our cohort is also just over 30% and approximately 40% based on ALS-FTD-Q and MiND-B. This is slightly less than that found by others [16, 30] (Table 2) .
Previous studies compared people with ALS with normal healthy controls [12, 24] or had no controls. Our controls came from the same population as the people with ALS. None of the controls had evidence of disease of central nervous system, although two had mitochondrial myopathy, which could indicate a multi-system disorder. Both the average scores and the frequency of cognitive impairment were significantly different between the groups. In the ACE-III subdomains, significant differences were found in attention and language. Our study did not find fluency difference between the two groups, in contrast to previous studies that compared ALS patients with healthy controls [47, 48] . We note that the tasks and scoring of fluency vary among the different tools, reducing the ability to compare results.
We used multiple logistic regression analysis to investigate factors that influence the development of cognitive or behavioural impairment in ALS. We found that age and years of education affect the cognition measured by ACE-III. This is unsurprising
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19 as age and years of education are known to affect cognitive performance in the healthy population [43] and to reduce the risk of dementia [49] . Age and lower levels of education have been observed in several previous ALS studies as risk factors for cognitive impairment [13, 21, 50] , although others found no significant effect of these factors [35, 51, 52] . Using age corrected or education level corrected scoring guide would be desirable in future studies of cognition in ALS.
Previously, some studies have found that people with bulbar onset of ALS are more likely to have cognitive impairment than those with spinal onset [39, 53, 54] , but others do not [33, 35, 55] . In our study, the site of onset had no effect of the presence of cognitive impairment as determined by the ACE-III, but site of onset influenced cognitive impairment based on FAB logistic regression results. In our cohort, the bulbar onset patients had decreased ratio of cognitive impairment and longer survival in the Cox regression model. This needs to be studied further.
In our cohort, the patients with cognitive or behavioral impairment based on ACE-III and ALS-FTD-Q had worse prognosis than the ones without. This is consistent with some previous studies [56, 57] but contrary to other studies [35, 58] . In our study, stereotypical behaviour, apathy, and disinhibition do not predict the survival of ALS patients, which is consistent with one previous study using the same scale [59] .
However another study found that the apathy measured with the revised version of the Cambridge behavioral inventory (CBI-R) is good indicator of survival [60] .
Classifying the patients into different level of cognitive and behavioral impairment could be better than using cutoff value in predicting the prognosis. A possible explanation for the worse prognosis of patients with cognitive impairment is that they have a disease that is more widespread and extensive than those with only motor symptoms. Another possibility is that those with cognitive impairment have different
causative genes than those without. The most prominent gene that causes ALS with cognitive impairment is C9orf72 [3, 4] , but there are others such as TARDBP and fused in sarcoma (FUS) [61, 62] .
In our longitudinal study, only a limited number of people had more than two tests. Because of variability in attendance at the clinic, the interval between two consecutive time points ranges from 6 months to 33 months. Therefore we used a generalized estimating equation (GEE) to investigate whether there is difference between first two serial tests. The GEE statistical model is very robust to abnormal distributions, missing data and heterogeneity in timing of measurement. No significant difference was found between the first two visits in both ACE-III and FAB, which
suggests that the cognitive test performance is relatively stable, and these patients who are cognitively normal at first testing will remain so over time. However, more people with ALS are needed at later time points to clarify this.
Previous studies showed conflicting results. One study found that in bulbar onset patients, cognitive impairment was progressive over time [39] , another found that 37% of patients developed cognitive deficit over a six month follow-up period [40] , and another found that cognitive impairment was greater at the later stages of disease, when only 14% of patients had normal cognition [41] , thus providing evidence that cognition is progressively affected in ALS. The previous serial studies of cognition are summarised in Table 8 . If there were a progressive deterioration of cognition over time, this could be due to the spread of pathology from motor regions to other regions, through prion-like spread, as has recently been proposed [63] . However, the finding that some patients have cognitive impairment at presentation while others remain cognitively normal throughout disease would be more consistent with ALS being a heterogeneous disease [38, 64] .
One weakness of this paper is that we have only limited genotyping. Another weakness is that we used simple screening tools that may not have detected subtle deficits. However, the tools that we have used are available for use in ALS clinics and provide evidence that some patients with ALS have cognitive impairment, which is a poor prognostic marker, that patients who are cognitively normal at onset show little evidence of deterioration over 6 months and possibly longer, and that age and education are risk factors for cognitive impairment in ALS.
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A C C E P T E D M A N U S C R I P T 5. Figure 5 : FAB longitudinal results in three different site of onset. The longitudinal curves were plotted in every patient according to different site of onset.
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